Evidence map›Paper›PMID 23880401›Full record

ArticleNeurobiology of disease2013

Intracellular and circulating neuronal antinuclear antibodies in human epilepsy.

Philip H Iffland, Juliana Carvalho-Tavares, Abhishek Trigunaite, Shumei Man, Peter Rasmussen, Andreas Alexopoulos, Chaitali Ghosh, Trine N Jørgensen, Damir Janigro

Open access · hybridAbstract read
In one paragraph

Article in Neurobiology of disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Inflammatory pathways of seizure disorders.Trends in neurosciences · 2014
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Philip H IfflandDepartment of Neurological Surgery, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA; Kent State University School of Biomedical Sciences, Kent, OH, USA. Electronic address: ifflanp@ccf.org.
Juliana Carvalho-Tavares
Abhishek Trigunaite
Shumei Man
Peter Rasmussen
Andreas Alexopoulos
Chaitali Ghosh
Trine N Jørgensen
Damir Janigro
Cleveland Clinic · USNeurological Surgery · USUniversidade Federal de Minas Gerais · BR

Funding

Drug brain biotransformation in human refractory epilepsyR01NS078307 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI GHOSH, CHAITALI, MARCHI, NICOLA · 2012 to 2016
$1.7M
MECHANISMS OF MULTIDRUG RESISTANCER01NS043284 · NINDS · CLEVELAND CLINIC LERNER COL/MED-CWRU · PI JANIGRO, DAMIR · 2002 to 2005
$1.3M
Development of a BBB model to study transendothelial cell migrationR42MH093302 · NIMH · FLOCEL, INC. · PI JANIGRO, DAMIR · 2012 to 2013
$1.0M
Serum markers of football-related brain concussions: a pilot studyR21NS077236 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI JANIGRO, DAMIR · 2011 to 2012
$393k
Development of predictive in vitro model of drug absorption across the human BBBR21HD057256 · NICHD · CLEVELAND CLINIC LERNER COM-CWRU · PI JANIGRO, DAMIR · 2009 to 2010
$391k
Development of a BBB Model to Study Transendothelial Cell MigrationR41MH093302 · NIMH · FLOCEL, INC. · PI JANIGRO, DAMIR · 2010 to 2011
$158k
NICHD NIH HHS R21 HD057256NICHD NIH HHS R21HD057256NIMH NIH HHS R41 MH093302NIMH NIH HHS R41MH093302NIMH NIH HHS R42 MH093302NIMH NIH HHS R42MH093302NINDS NIH HHS R01 NS043284NINDS NIH HHS R01 NS078307NINDS NIH HHS R01NS078307NINDS NIH HHS R01NS43284NINDS NIH HHS R21 NS077236NINDS NIH HHS R21NS077236
6 · The paper itself

Abstract

There are overwhelming data supporting the inflammatory origin of some epilepsies (e.g., Rasmussen's encephalitis and limbic encephalitis). Inflammatory epilepsies with an autoimmune component are characterized by autoantibodies against membrane-bound, intracellular or secreted proteins (e.g., voltage gated potassium channels). Comparably, little is known regarding autoantibodies targeting nuclear antigen. We tested the hypothesis that in addition to known epilepsy-related autoantigens, the human brain tissue and serum from patients with epilepsy contain autoantibodies recognizing nuclear targets. We also determined the specific nuclear proteins acting as autoantigen in patients with epilepsy. Brain tissue samples were obtained from patients undergoing brain resections to treat refractory seizures, from the brain with arteriovenous malformations or from post-mortem multiple sclerosis brain. Patients with epilepsy had no known history of autoimmune disease and were not diagnosed with autoimmune epilepsy. Tissue was processed for immunohistochemical staining. We also obtained subcellular fractions to extract intracellular IgGs. After separating nuclear antibody-antigen complexes, the purified autoantigen was analyzed by mass spectrometry. Western blots using autoantigen or total histones were probed to detect the presence of antinuclear antibodies in the serum of patients with epilepsy. Additionally, HEp-2 assays and antinuclear antibody ELISA were used to detect the staining pattern and specific presence of antinuclear antibodies in the serum of patients with epilepsy. Brain regions from patients with epilepsy characterized by blood-brain barrier disruption (visualized by extravasated albumin) contained extravasated IgGs. Intracellular antibodies were found in epilepsy (n=13/13) but not in multiple sclerosis brain (n=4/4). In the brain from patients with epilepsy, neurons displayed higher levels of nuclear IgGs compared to glia. IgG colocalized with extravasated albumin. All subcellular fractions from brain resections of patients with epilepsy contained extravasated IgGs (n=10/10), but epileptogenic cortex, where seizures originated from, displayed the highest levels of chromatin-bound IgGs. In the nuclear IgG pool, anti-histone autoantibodies were identified by two independent immunodetection methods. HEp-2 assay and ELISA confirmed the presence of anti-histone (n=5/8) and anti-chromatin antibodies in the serum from patients with epilepsy. We developed a multi-step approach to unmask autoantigens in the brain and sera of patients with epilepsy. This approach revealed antigen-bound antinuclear antibodies in neurons and free antinuclear IgGs in the serum of patients with epilepsy. Conditions with blood-brain barrier disruption but not seizures, were characterized by extravasated but not chromatin-bound IgGs. Our results show that the pool of intracellular IgG in the brain of patients with epilepsy consists of nucleus-specific autoantibodies targeting chromatin and histones. Seizures may be the trigger of neuronal uptake of antinuclear antibodies.

Indexed as

EpilepsyAdolescentAdultAntibodies, AntinuclearBlood-Brain BarrierBrainChildChromatinDNAFemaleHistonesHumansImmunoglobulin GInfantMaleMicrotubule-Associated ProteinsAntibodies, AntinuclearChromatinDNAHistonesImmunoglobulin GMicrotubule-Associated ProteinsAnti-chromatin antibodyAnti-histone antibodyAutoantibodyAutoantigenAutoimmuneNeuroimmunologySeizure disorders

Identifiers

PMID23880401
PMCPMC3900287
OpenAlexW1967316844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.